Geron news from FierceBiotech
NewsFDA's delay of Geron ESC trial raises concerns
Getting an embryonic stem cell therapy through clinical trials in the U.S. is looking like an increasingly tough challenge after Geron announced that the FDA is delaying a study of its experimental Read more...
What's in store for stem cell treatments?
At yesterday's hearing on stem cells, the FDA set a high bar for the treatments, saying Read more...
ALSO NOTED: YM cleared for Phase II; pine needle approach studied for ulcers; Applera in buyback plan; and much more...
> YM BioSciences has received FDA approval initiate a Phase II trial investigating nimotuzumab in pediatric patients. Read more...
| Press ReleasesPRESS RELEASE: Stem Cells Improve Heart Function After Heart Attack GERON SCIENTISTS AND COLLABORATORS DEMONSTRATE HUMAN EMBRYONIC STEM CELL-DERIVED CARDIOMYOCYTES IMPROVE HEART FUNCTION WHEN TRANSPLANTED AFTER MYOCARDIAL INFARCTION Landmark Read more... |
Get more Geron coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets